Skip to content
HOME beyond traditional animal models

Move Beyond Traditional Animal Models

Partner with Ncardia to move beyond animal models with iPSC-based platforms that improve safety, translation and efficiency.

Ncardia Leads the Way With iPSC-Derived Platforms

As pioneers in iPSC technology, Ncardia helps you move beyond traditional animal models with innovative, scalable and human-relevant solutions that meet the FDA’s animal testing requirements outlined in the “Roadmap to Reduce Animal Testing in Preclinical Safety Studies.”

Let’s work together to align your programs with the FDA’s new standards and build a better path to the clinic.

Innovative Platforms to Reduce Animal Testing in Cardiotoxicity Research

Improve translational relevance, reduce timelines and minimize animal use to move confidently toward Investigational New Drug (IND) submission

What Is the FDA’s “Roadmap to Reduce Animal Testing in Preclinical Safety Studies”?
The FDA’s latest guidance encourages the adoption of New Approach Methodologies (NAMs) as scientifically valid alternatives to animal testing.

 

Read our blog for a full breakdown of the roadmap and its implications 

 

Ncyte® vCardiomyocytes

Ncyte® vCardiomyocytes are physiologically relevant, functional ventricular cardiomyocytes (vCMs) built from human iPSC-derived cells and validated across a robust set of key safety pharmacology and cardiotoxicity assays. Perfectly adaptable to all assays’ needs, our vCMs offer a scalable, reproducible, stable and consistent solution for confidently integrating human-relevant cardiac models into your research.

Whether you need our in-house screening services or a reliable cell supply, we provide flexible delivery volumes of up to 10 billion cells per batch to meet your screening campaign’s needs.

Contact us to Get Started

Ncyte® vCardiomyocytes are the ideal model for high-throughput cardiotoxicity and preclinical safety studies — and we have the data to back it up.

 

       
Ncyte® Heart in a Box™

Ncyte® Heart in a Box™ is the only 100% iPSC-based, completely automatic 3D Cardiac model. It’s high-throughput, optimized for 384-well plate formats and fully compatible with automated screening pipelines — allowing you to capture up to 1,500 data points per day in a complex 3D model.

Our in-house 3D assay capabilities include calcium transient analysis (FDSS), cardiac fibrosis and ischemia-reperfusion studies.

Contact us to Get Started

Get a closer look at how Ncyte® Heart in a Box™ offers the perfect balance of assay throughput with physiological relevance.

 

Coming Soon: Ncyte® NHP-C vCardiomyocytes

Ncyte® NHP-C vCardiomyocytes are the first-ever non-human primate (NHP)-derived cardiomyocytes available for research use. Made from the cynomolgus macaque, they offer a reliable in vitro alternative to in vivo NHP testing in support of more ethical, translationally aligned preclinical safety research.

Want to be among the first to experience this groundbreaking model?

Contact us for early access

Your Road to Reducing Animal Testing

Ncardia Leads the Way

As the FDA redefines the path to preclinical safety, drug developers must shift from traditional animal models to scientifically validated New Approach Methods (NAMs).

2022

FDA Modernization Act 2.0

This guidance removed the requirement for animal testing prior to human trials in most cases.

2024

FDA Science Board Endorses NAMs

As part of regulatory science modernization, the FDA recommended the use of NAMs.

2025

Roadmap to Reducing Animal Testing

The latest guidance further supports integration of NAMs and ushers in a paradigm shift away from animal models.